• 1
    Simon A, Levenson J. Stratification of vascular risk in hypertension and therapeutic perspective. Am J Hypertens. 1995;8:45S48S.
  • 2
    Ezzati M, Hoorn SV, Rodgers A, et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet. 2003;362:271280.
  • 3
    Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 4
    Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88:14441455.
  • 5
    Skilton MR, Serusclat A, Sethu AH, et al. Noninvasive measurement of carotid extra-media thickness: associations with cardiovascular risk factors and intima-media thickness. JACC Cardiovasc Imaging. 2009;2:176182.
  • 6
    Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation. 2008;118:961967.
  • 7
    Jensen JS, Feldt-Rasmussen B, Strandgaard S, et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension. 2000;35:898903.
  • 8
    Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144:172180.
  • 9
    Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003;108:21542169.
  • 10
    Levy D, Salomon M, D’Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:17861793.
  • 11
    Cuspidi C, Ambrosioni E, Mancia G, et al. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the assessment of prognostic risk observational survey. J Hypertens. 2002;20:13071314.
  • 12
    Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345352.
  • 13
    Zanchetti A, Hansson L, Dahlof B, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the hypertension optimal treatment study. Hot study group. J Hypertens. 2001;19:11491159.
  • 14
    Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens. 2004;22:479486.
  • 15
    Thoenes M, Tebbe U, Rosin L, et al. Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists. Clin Res Cardiol. 2011;100:483491.
  • 16
    Wittchen HU, Glaesmer H, Marz W, et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the Detect program. Curr Med Res Opin. 2005;21:619630.
  • 17
    Zeymer U, Dechend R, Deeg E, Kaiser E, Senges J, Pittrow D, Schmieder R. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. Int J Clin Pract. 2012;66:251261.
  • 18
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34(suppl 1):S62S69.
  • 19
    Leoncini G, Sacchi G, Viazzi F, et al. Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J Hypertens. 2002;20:13151321.
  • 20
    Gomez Marcos MA, Gonzalez-Elena LJ, Recio-Rodriguez JI, et al. Cardiovascular risk assessment in hypertensive patients with tests recommended by the European guidelines on hypertension. Eur J Cardiovasc Prev Rehabil. 2011 Mar 10. [Epub ahead of print]
  • 21
    Korhonen PE, Vesalainen RK, Aarnio PT, et al. The assessment of total cardiovascular risk in hypertensive subjects in primary care. Ann Med. 2010;42:187195.
  • 22
    Cea-Calvo L, Conthe P, Gomez-Fernandez P, et al. Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. Cardiovasc Diabetol. 2006;5:23.
  • 23
    Viazzi F, Parodi D, Leoncini G, et al. Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens. 2004;22:907913.
  • 24
    Redon J, Cea-Calvo L, Lozano JV, et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study. J Hypertens. 2006;24:663669.
  • 25
    Viazzi F, Leoncini G, Parodi D, et al. Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. J Am Soc Nephrol. 2005;16(Suppl 1):S89S91.
  • 26
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (life): a randomised trial against atenolol. Lancet. 2002;359:10041010.
  • 27
    Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the life study. Ann Intern Med. 2003;139:901906.
  • 28
    Raum E, Lietzau S, Stegmaier C, et al. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany. Pharmacoepidemiol Drug Saf. 2008;17:485494.
  • 29
    Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:23632369.